MSA
SRPT icon

Marino Stram & Associates’s Sarepta Therapeutics SRPT Stock Holding History

Marino Stram & Associates’s Portfolio SRPT Stock Details SRPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q2 		– Sell
-15
Closed -$2K – 486
2019
Q1 		$2K Hold
15
– – ﹤0.01% 550
2018
Q4 		$2K Buy
+15
New +$1.88K ﹤0.01% 509

Other funds holding SRPT

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Sands Capital Management
Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Fidelity International
Fidelity International Hamilton, Bermuda $129B AUM 30.83% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Marino Stram & Associates's SRPT Position: Q2 2019 in Review

Marino Stram & Associates sold out of Sarepta Therapeutics (SRPT) in Q2 2019, closing a stake of 15 shares — an estimated $2K sold.

Marino Stram & Associates first reported a position in SRPT in Q4 2018 and held it in 2 quarters. The position peaked at $2K in Q1 2019. 365 funds tracked by Wall St. Rank hold SRPT as of Q2 2019.

  • Marino Stram & Associates reported no remaining Sarepta Therapeutics position as of Q2 2019 after selling out during the quarter.
  • Marino Stram & Associates sold 15 Sarepta Therapeutics shares in Q2 2019, an estimated $2K.
  • Marino Stram & Associates first reported a position in Sarepta Therapeutics in Q4 2018 and held it in 2 quarters.
  • Marino Stram & Associates's Sarepta Therapeutics position peaked at $2K in Q1 2019.
  • 365 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q2 2019.

Based on Marino Stram & Associates's 13F filing for Q2 2019, filed 19 Jul 2019.